Home/Academy/Journal Finder/Signal Transduction and Targeted Therapy
Signal Transduction and Targeted Therapy
Springer Nature (Nature Portfolio)
Signal transduction in physiological and pathological processes, and targeted therapeutics including biological agents and small-molecule drugs
Overview
Signal Transduction and Targeted Therapy is published by Springer Nature (Nature Portfolio). Signal transduction in physiological and pathological processes, and targeted therapeutics including biological agents and small-molecule drugs
Key information
Editors-in-Chief as listed on the journal’s nature.com pages. The article processing charge is still to be verified.
Aims & scope
An international, peer-reviewed, open-access journal. It is multidisciplinary, spanning:
- Molecular and cell biology
- Pharmacology and medicinal chemistry
- Computational chemistry
- Systems biology and bioinformatics
- Clinical medicine
Covers signal transduction in health and disease, and targeted therapeutics such as biological agents and small-molecule drugs. Publishes primary research as well as reviews.
No per-article-type breakdown verified yet for this journal.
General formatting rules that apply across article types. Specific word, abstract, reference and figure limits vary by article type — see the Article types tab for those.
General requirements
Manuscript template
Not yet verified
Information on the submission process and the ethics and publication standards Signal Transduction and Targeted Therapy applies.
Submission process
Ethics & publication standards
Not yet verified
Author guidelines
Read the complete and latest author instructions on the journal website.
View author guidelinesData availability
Not yet verified
Document and declaration checklists (cover letter, disclosures, registration numbers, etc.) follow ICMJE recommendations generally — we have not independently itemized Signal Transduction and Targeted Therapy's exact required-documents list, so check the live author guidelines before submitting.
Sample articles
Recent, relevant articles published in Signal Transduction and Targeted Therapy. These examples help you understand the journal's scope, style and expected quality — we only list one once its title, DOI, year and article type are verified against the publisher's own page.
Filter examples
Article type
Learn from examples
- Review the structure, formatting and presentation style the journal actually publishes.
- Use examples together with the Article types and Manuscript specs tabs, not as a substitute for the journal's own guidelines.
- Check article-type-specific requirements before drafting.
Confirmed against each article’s PubMed record (title, authors, date, volume and DOI). Article type follows PubMed; replace with the journal’s own section label when known.
General stages a manuscript moves through at most peer-reviewed journals — this sequence is standard academic-publishing practice, not a claim we've verified against Signal Transduction and Targeted Therapy's own workflow. Durations below are shown only where the publisher has actually disclosed them.
Manuscript submitted via the journal's submission system.
Administrative and scope check by the editorial office.
Editor decides whether to send the manuscript for peer review.
External review by expert referees.
Accept, minor/major revision, or reject.
Author submits a revised manuscript, if requested.
Editor confirms acceptance.
Online-first, then the print/issue assignment if applicable.
Key timeline statistics
Factors that may affect timeline
- Type and complexity of the study
- Speed of author response to reviewer comments
- Number of revision rounds
- Availability of expert reviewers
- Editorial and production workload
- Compliance with the journal's own guidelines
General tips for faster processing
- Confirm the manuscript fits the journal's scope before submitting
- Follow the author guidelines and formatting requirements closely
- Respond to reviewer comments completely and promptly
- Submit all required documents and declarations at the time of submission
The stage sequence and general tips above reflect typical academic-publishing practice, not data we've verified against Signal Transduction and Targeted Therapy specifically. Any duration we haven't independently confirmed from the publisher reads as "not yet verified" rather than an estimate.
Indexing and abstracting services
Scopus coverage confirmed through the SCImago record; listed in DOAJ. Other databases are still to be verified.
Citation metrics
Not yet verified
Requires a licensed Scopus/JCR/SCImago lookup we have not run for this title.
Not yet verified
Requires a licensed Scopus/JCR/SCImago lookup we have not run for this title.
Only the figures listed are on record here. Confirm on JCR, Scopus or SCImago before citing.
Not yet verified
Requires a licensed Scopus/JCR/SCImago lookup we have not run for this title.
Journal quartile
Scopus and Web of Science classify journals into their own category sets — we show the one subject category we've confirmed rather than listing categories we haven't checked.
Additional metrics
CiteScore details (2024)
Metric notes
- SCImago 2025: SJR 17.740, Q1, h-index 224; 423 documents in 2025.
- The Impact Factor and CiteScore are not yet verified from Clarivate or Scopus, so they are not shown.
Publication charges and author-facing fees. Springer Nature (Nature Portfolio) has not published a per-route APC schedule we could independently verify for Signal Transduction and Targeted Therapy — every amount below is honestly unknown rather than estimated, not a $0 fee.
Publication charges (APC)
Additional charges
Check current fees
Publication-charge and open-access policy pages change independently of this profile.
Visit journal websiteLicence & copyright
- Publishing agreements and licence terms are set by the publisher and vary by publishing route.
- We have not independently verified Signal Transduction and Targeted Therapy's specific licence (e.g. a named Creative Commons variant) — confirm on the journal website before relying on it.
Based on what Springer Nature (Nature Portfolio) has publicly stated for Signal Transduction and Targeted Therapy as of our last check — verify current fees and policy on the journal website before budgeting or submitting.
- Best fit for manuscripts in signal transduction in physiological and pathological processes, and targeted therapeutics including biological agents and small-molecule drugs — not a narrow subspecialty-only readership.
These notes are Pubrica's own read of the journal's published guidelines, not a claim about editorial preference or acceptance likelihood.
From the journal’s nature.com pages (journal information, aims & scope) and DOAJ as returned by search, SCImago 2025 and PubMed records for the sample articles, November 2026.